San Jose, Calif. – July 30, 2019 – Molecular Devices, LLC, a leader in protein and cell biology technologies, today announced the launch of the next generation of its FLIPR® Penta High-Throughput Cellular Screening System.
The new FLIPR Penta system builds on the success of the industry-leading FLIPR® platform for monitoring of GPCRs and ion channels, offering a new high-speed camera option capable of capturing key dynamics of iPSC-derived neuronal and cardiac stem cells at higher frame resolution. Additionally, the new ScreenWorks® Peak ProTM 2 software adds capabilities to translate these higher resolution signals into key insights, adding over 30 new measurements to the analysis package.
“The expanded capabilities of the FLIPR Penta system will allow scientists studying organoids and stem cell-derived neuronal and cardiac cells to have a better understanding of toxic compound effects,” explains Sarah Vargas-Hurlston, Sr. Director of Marketing, Drug Discovery. “Combined with our extensive line of assay kits, this new FLIPR system will enable breakthrough research in ion channels using stem cell models.”
For more information, visit http://www.moleculardevices.com.
About Molecular Devices, LLC
Molecular Devices is one of the world's leading providers of high-performance bioanalytical measurement systems, software and consumables for life science research, pharmaceutical and biotherapeutic development. Included within a broad product portfolio are platforms for high-throughput screening, genomic and cellular analysis, colony selection and microplate detection. These leading-edge products enable scientists to improve productivity and effectiveness, ultimately accelerating research and the discovery of new therapeutics. Molecular Devices is committed to the continual development of innovative solutions for life science applications. The company is headquartered in Silicon Valley, California with offices around the globe.
Sr. Director of Marketing, Drug Discovery